Continuous dopaminergic stimulation in the management of complicated Parkinson's disease
Agnoli, A.; Stocchi, F.; Carta, A.; Antonini, A.; Bragoni, M.; Ruggieri, S.A.
Mount Sinai Journal of Medicine new York 55(1): 62-66
1988
ISSN/ISBN: 0027-2507 PMID: 3258057 Document Number: 325409
Document emailed within 1 workday
Related Documents
1997: Therapy of Parkinson disease. Continuous physiologic dopaminergic stimulation with carbergoline Der Nervenarzt 68(3 Suppl Therapie D): 1-4Destée, A..; Bordet, R.. 2002: Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation Revue Neurologique (Paris) 158(122): 69-82
Destée, A.; Bordet, R. 2002: Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation Revue Neurologique (Paris) 158(Special Issue 1): S69-S82
Maggio, R.; Barbier, P.; Corsini, G.U. 1995: Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response Journal of Neural Transmission. Supplementum 45: 133-136
Pirtošek, Z. 2011: Myths and realities of continuous dopaminergic stimulation Psychiatria Danubina 23(1): 80-83
Jenner, P. 2004: Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation Neurology 62(1 Suppl 1): S47-S55
Korczyn, A.D. 2003: Dopaminergic drugs in development for Parkinson's disease Advances in Neurology 91: 267-271
Zabek, M.; Mazurowski, W.; Dymecki, J.; Stelmachów, J.; Gawur, B.; Trautsolt, W.; Zawada, E. 1992: Transplantation of fetal dopaminergic cells in Parkinson disease Neurologia i Neurochirurgia Polska Suppl 1: 13-19
Duvoisin, R.C. 1989: New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation Neurology 39(11 Suppl 2: 4-6
Ishida, Y. 2005: Psychiatric symptoms of Parkinson's disease--an overview from the studies on dopaminergic nerves Seishin Shinkeigaku Zasshi 107(3): 290-293
Clough, C.G.; Bergmann, K.J.; Yahr, M.D. 1984: Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration Advances in Neurology 40: 131-140
Prabhakar, S.; Syal, P.; Srivastava, T. 2000: P300 in newly diagnosed non-dementing Parkinson's disease: effect of dopaminergic drugs Neurology India 48(3): 239-242
Hirsch, E.C. 2000: Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment Annals of Neurology 47(4 Suppl 1): S115
Lefaucheur, J.P. 2005: Motor cortex stimulation for Parkinson's disease and dystonia: lessons from transcranial magnetic stimulation? A review of the literature Revue Neurologique (Paris) 161(1): 27-41
Bertrand, E.; Lechowicz, W.; Szpak, G.M.; Dymecki, J. 1997: Current views on the mechanisms of dopaminergic neuron death of the nigrostriatal system in Parkinson's disease Neurologia i Neurochirurgia Polska 31(2): 295-302
Melamed, E.; Hefti, F.; Wurtman, R.J. 1982: Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model Israel Journal of Medical Sciences 18(1): 159-163
Pokhabov, D.V.; Rudnev, V.A.; Prokopenko, S.V. 2003: The experience of dopaminergic agent decreased dosage with rhythmic pace gait correction in Parkinson disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 103(8): 76-77
Zheng, L.; Wang, H.; Ba, Y.-Y.; Liu, H.-L.; Wang, M.; Guo, W.-W.; Wu, X.; Yang, H. 2014: Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease Zhongguo Zhong Yao Za Zhi 39(9): 1660-1665
Cadiot, G. 1999: Management of complicated and non complicated gastric and duodenal ulcer disease Gastroenterologie Clinique et Biologique 23(10 Part 2): C34-C47
Chase, T.N.; Baronti, F.; Fabbrini, G.; Heuser, I.J.; Juncos, J.L.; Mouradian, M.M. 1989: Rationale for continuous dopaminomimetic therapy of Parkinson's disease Neurology 39(11 Suppl 2: 7